Evidence map›Paper›PMID 38288313›Full record

ArticleBMJ neurology open2024

Impaired mobility and MRI markers of vascular brain injury: Atherosclerosis Risk in Communities and UK Biobank studies.

Richa Sharma, Adam de Havenon, Cyprien Rivier, Seyedmehdi Payabvash, Rachel Forman, Harlan Krumholz, Guido J Falcone, Kevin N Sheth, Walter N Kernan

Abstract read
In one paragraph

Article in BMJ neurology open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Richa SharmaDepartment of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0003-0798-2353
Adam de HavenonDepartment of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0001-8178-8597
Cyprien RivierDepartment of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.
Seyedmehdi PayabvashDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0003-4628-0370
Rachel FormanDepartment of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.
Harlan KrumholzDepartment of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Guido J FalconeDepartment of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.
Kevin N ShethDepartment of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.
Walter N KernanDepartment of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Denise Esserman · 2002 to 2026
$37.9M
Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)U01NS106513 · NINDS · YALE UNIVERSITY · PI Hooman Kamel, Kevin Navin Sheth · 2019 to 2026
$20.6M
The Recovery in Stroke Using PAP (RISE UP) StudyR01NR018335 · NINR · YALE UNIVERSITY · PI REDEKER, NANCY S, SHETH, KEVIN NAVIN · 2019 to 2023
$3.4M
Southern New England Partnership In Stroke Research, Innovation and Treatment (SPIRIT)U24NS107215 · NINDS · YALE UNIVERSITY · PI MARK Jay ALBERTS, Karen L Furie · 2018 to 2026
$3.0M
Yale Clinical Site: Investigations For Improved Neurological Treatments at Yale (INFINITY)U24NS107136 · NINDS · YALE UNIVERSITY · PI SHETH, KEVIN NAVIN, SPUDICH, SERENA S · 2018 to 2022
$1.7M
Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRIK23NS105924 · NINDS · YALE UNIVERSITY · PI DE HAVENON, ADAM H. · 2019 to 2023
$988k
Classification of Stroke Etiology Using Advanced Computational ApproachesK23NS121634 · NINDS · YALE UNIVERSITY · PI Richa Sharma · 2022 to 2026
$951k
Intensive Blood Pressure Reduction in Deep Intracerebral HemorrhageR03NS112859 · NINDS · YALE UNIVERSITY · PI FALCONE, GUIDO JOSE, SHETH, KEVIN NAVIN · 2019 to 2020
$84k
NCATS NIH HHS UL1 TR001863NIA NIH HHS K76 AG059992NIA NIH HHS P30 AG021342NINDS NIH HHS K23 NS105924NINDS NIH HHS K23 NS121634NINDS NIH HHS R03 NS112859NINDS NIH HHS U01 NS106513NINDS NIH HHS U24 NS107136NINDS NIH HHS U24 NS107215NINR NIH HHS R01 NR018335
6 · The paper itself

Abstract

Background: Vascular brain injury (VBI) may be an under-recognised contributor to mobility impairment. We examined associations between MRI VBI biomarkers and impaired mobility. Methods: We separately analysed Atherosclerosis Risk in Communities (ARIC) and UK Biobank (UKB) study cohorts. Inclusion criteria were no prevalent clinical stroke, and available brain MRI and balance and gait data. MRI VBI biomarkers were (ARIC: ventricular and white matter hyperintensity (WMH) volumes, non-lacunar and lacunar infarctions, microhaemorrhage; UKB: ventricular, brain and WMH volumes, fractional anisotropy (FA), mean diffusivity (MD), intracellular and isotropic free water volume fractions). Quantitative biomarkers were categorised into tertiles. Mobility impairment outcomes were imbalance and slow walk in ARIC and recent fall and slow walk in UKB. Adjusted multivariable logistic regression analyses were performed. Results: We included 1626 ARIC (mean age 76.2 years; 23.4% imbalance, 25.0% slow walk) and 40 098 UKB (mean age 55 years; 15.8% falls, 2.8% slow walk) participants. In ARIC, imbalance associated with four of five VBI measures (all p values<0.05), most strongly with WMH (adjusted OR, aOR 1.64; 95% CI 1.18 to 2.29). Slow walk associated with four of five VBI measures, most strongly with WMH (aOR 2.32; 95% CI 1.66 to 3.24). In UKB, falls associated with all VBI measures except WMH, most strongly with FA (aOR 1.16; 95% CI 1.08 to 1.24). Slow walking associated with WMH, FA and MD, most strongly with FA (aOR 1.57; 95% CI 1.32 to 1.87). Conclusions: VBI is associated with mobility impairment in community-dwelling, clinically stroke-free cohorts. Consequences of VBI may extend beyond clinically apparent stroke to include mobility.

Indexed as

STROKE

Identifiers

PMID38288313
PMCPMC10823923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.